Influence of antithrombin III on coagulation and inflammation in porcine septic shock

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 19, Issue 6, 1999, Pages 1566-1572

  Dickneite, Gerhard ^a,c,d   Leithäuser, Boris ^b  

^a Centeon Pharma GmbH   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c Centeon Pharma GmbH   (Germany)

^d Emil Von Behring Straße 76   (Germany)

Author keywords

Disseminated intravascular coagulation; Lipopolysaccharide; Pulmonary hypertension; Soluble fibrin monomers; Thromboxane

Indexed keywords

ANTITHROMBIN III; BACTERIUM LIPOPOLYSACCHARIDE; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG EFFECT; DRUG SCREENING; HYPOTENSION; MALE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SEPTIC SHOCK; SWINE;

EID: 0345211570     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.19.6.1566     Document Type: Article

References (44)

1. Parillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med. 1990;113:227-242.
2. Centers for Disease Control. Chronic disease reports: Deaths from nine chronic diseases - United States, 1986. Morb Mort Weekly Rep. 1990;39: 17-36.
3. Ziegler-Heitbrock HWL, Ulevitch RJ. CD14: Cell surface receptor and differentiation marker. Immunol Today. 1993;14:121-125.
4. Bick RL. Disseminated intravascular coagulation: Objective clinical and laboratory diagnosis, treatment, and assessment of therapeutic response. Semin Thromb Hemost. 1996;22:69-88.
5. Olds RJ, Lane DA, Mille B, Chowdhury V, Thein SL. Antithrombin: The principle inhibitor of thrombin. Semin Thromb Hemost. 1994;20: 353-372.
6. Olson ST, Björk I. Regulation of thrombin activity by antithrombin and heparin. Semin Thromb Hemost. 1994;20:373-409.
7. Soons H, Tans G, Hemker HC. The heparin-catalysed inhibition of human factor XIa by antithrombin III is dependent on the heparin type. Biochem J. 1998;256:815-820.
8. a by antithrombin III/heparin during factor X activation. J Biol Chem. 1988; 263:15313-15318.
9. Stead N, Kaplan AP, Rosenberg RD. Inhibition of activated factor XII by antithrombin-heparin cofactor. J Biol Chem. 1976;251:6481-6488.
10. Venneröd AM, Laake K, Solberg AK, Strömland S. Inactivation and binding of human plasma kallikrein by antithrombin III and heparin. Thromb Res. 1976;9:457-466.
11. Taylor FB Jr, Emerson TE Jr, Jordan R, Chang AK, Blick KE. Antithrombin-III prevents the lethal effects of escherichia coli infusion in baboons. Circ Shock. 1988;26:227-235.
12. Hauptman JG, Hassouna HI, Bell TG, Penner JA, Emerson TE. Efficacy of antithrombin III in endotoxin-induced disseminated intravascular coagulation. Circ Shock. 1988;25:111-122.
13. Phillips TF, Mammen EF, Selik NR, Starico A, Assarian GS, Kihm JT, Murano G. Experimentelle Verbrauchkoagulopathie - Behandlung mit Antithrombin III. Med Welt. 1984;35:1022-1026.
14. Mammen EF, Miyakawa T, Phillips TF, Assarian GS, Brown JM, Murano G. Human antithrombin concentrates and experimental disseminated intravascular coagulation. Semin Thromb Hemost. 1985;11:373-383.
15. 1-proteinase inhibitor in the E. coli endotoxemic sheep pulmonary dysfunction model. Circ Shock. 1988;26:15-26.
16. Triantaphyllopoulos DC. Effects of human antithrombin III on mortality and blood coagulation induced in rabbits by endotoxin. Thromb Haemost. 1984;51:232-235.
17. Gó7mez C, Páramo JA, Colucci M, Rocha E. Effect of heparin and/or antithrombin III on the generation of endotoxin-induced plasminogen activator inhibitor. Thromb Haemost. 1989;62:694-698.
18. Dickneite G, Pâques EP. Reduction of mortality with antithrombin III in septicemic rats: A study of Klebsiella pneumoniae-induced sepsis. Thromb Haemost. 1993;69:98-102.
19. Emerson TE, Fournel MA Jr, Leach WJ, Redens TB. Protection against disseminated intravascular coagulation and death by antithromhin-III in the escherichia coli endotoxemic rat. Circ Shock. 1987;21:1-13.
20. Mann LT Jr, Jensenius JCHR, Simonsen M. Antithrombin III: Protection against death after injection of thromboplastin. Science. 1969;166: 517-518.
21. Kessler CM, Tang ZC, Jacobs HM, Szymannski LM. The suprapharmacologic dosing of antithrombin concentrate for Staphylococcus aureus-induced disseminated intravascular coagulation in guinea pigs: Substantial reduction in mortality and morbidity. Blood. 1997;89:4393-4401.
22. Menache D, Grossman BJ, Jackson CM. Antithrombin III: physiology, deficiency, and replacement therapy. Transfusion. 1992;32:580-588.
23. Vinazzer HA. Antithrombin III in shock and disseminated intravascular coagulation. Clin Appl Thromb Hemostas. 1995;1:62-65.
24. Eisele B, Lamy M, Thijs LG, Keinecke HP, Schuster F, Matthias R, Fourrier F, Heinrichs H, Delvos U. Antithrombin III in patients with severe sepsis. Intensive Care Med. 1998;24:663-672.
25. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Effects of antithrombin III (ATIII) and TRP 49-modified ATIII on plasma level of 6-keto-PGF 1α in rats. Thromb Res. 1995;80:201-208.
26. Dickneite G, Czech J, Keuper H. Formation of fibrin monomers in experimental disseminated intravascular coagulation and its inhibition by recombinant hirudin. Cire Shock. 1994;42:183-189.
27. Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Hemost. 1998;24:61-69.
28. Matthias FR. Hemostasis inbalance with sepsis. Pathogenetic value and therapeutic implications. Intensivmed. 1996;33:1-4.
29. Leithäuser B, Matthias FR. Microcirculation and hemostasis in inflammatory processes. Med Klin. 1997;92:426-431.
30. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993;104: 882-888.
31. Dickneite G, Czech J. Combination of antibiotic treatment with the thrombin inhibitor recombinant hirudin for the therapy of experimental Klebsiella pneumoniae sepsis. Thromb Haemost. 1994;71:768-772.
32. Spannagl M, Hoffmann H, Siebeck M, Weipert J, Schwarz HP, Schramm W. A purified antithrombin III - heparin complex as a potent inhibitor of thrombin in porcine endotoxin shock. Thromb Res. 1991;61:1-10.
33. Okajima K. New therapeutic implications of antithrombin III replacement in disseminated intravascular coagulation and multiple organ failure. Intensivmed. 1996;33:5-11.
34. Stern D, Nawroth P, Marcum J, Handley D, Kisiel W, Rosenberg R, Stern K. Interaction of antithrombin III with bovine aortic segments. J Clin Invest. 1985;75:272-279.
35. Yamauchi T, Umeda F, Inoguchi T, Nawata H. Antithrombin III stimulates prostacyclin production by cultured aortic endothelial cells. Biochem Biophys Res Commun. 1989;163:1403-1411.
36. Hone S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res. 1990; 59:895-904.
37. Uchiba M, Okajima K, Murakami K, Okabe H, Takatsuki K. Attenuation of endotoxin-induced pulmonary vascular injury by antithrombin III. Am J Physiol. 1996;270:L921-L930.
38. Voigt A, Sawitzky D, Zeichhard H, Habermehl KO. Cellular receptor structures for pseudorabies virus are blocked by antithrombin III. Med Microbiol Immunol (Berl). 1995:184:97-103.
39. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/reperfusion. Circulation. 1997; 96:2302-2310.
40. Seeger W, Neuhof H, Hall J, Roka L. Pulmonary vasoconstrictor response to soluble fibrin in isolated lungs: Possible role of thromboxane generation. Circ Res. 1988;62:651-659.
41. Fourrier F, Chopin C, Goudemand J. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of anti-thrombin III, protein C and protein S deficiencies. Chest. 1992;101: 816-823.
42. Jochum M. Influence of high-dose antithrombin concentrate therapy on the release of cellular proteinases, cytokines, and soluble adhesion molecules in acute inflammation. Semin Hematol. 1995;32:14-32.
43. Obertacke U, Kleinschmidt C, Jochum M, Bardenheuer M, Dresing K, Eisold C, Neudeck F. Reduction of shock-related complications and pulmonary microvascular permeability by continuous application of antithrombin III (140% serum activity) for 4 days after trauma - preliminary results of a prospective clinical study. Circ Shock. 1993;(suppl 1):41. Abstract.
44. Thijs LG, Eisele B, Keinecke HO, Knaub S, Heinrichs H. Antithrombin III in patients with severe sepsis - a dosage regimen finding and pharmacokinetic study. Intensive Care Med. 1997;23:58. Abstract.